$GSK

Funko surges 25% on sale speculation amid activist pressure. Entertainment sector sees major M&A activity including Paramount-Skydance deal and Caesars takeover interest.

GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.

GSK acquires 35Pharma for $950M to gain HS235, a clinical-stage pulmonary hypertension drug with improved safety profiles versus existing treatments.

Global anti-snoring devices market projected to nearly double to $3.36 billion by 2033, driven by obesity, health awareness, and technological advances.

Sexual health supplement market projected to grow 40% to $5.31 billion by 2030, driven by consumer wellness awareness and demand for natural, personalized products.

European political turmoil and sealed document disclosures trigger UK government resignations, rattling gilt markets. Rising borrowing costs compound concerns as UK economy stagnates with minimal growth.

Merck's RSV antibody Enflonsia shows positive Phase 3 results, supporting FDA expansion plans to protect more at-risk infants from respiratory syncytial virus infection.

European regulators approve GSK's Exdensur, a biannual asthma injection targeting type 2 inflammation. The drug also treats chronic rhinosinusitis with nasal polyps, showing significant exacerbation reductions in trials.

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.